Clinical Science| Volume 207, ISSUE 6, P824-831, June 2014

Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study

Published:October 10, 2013DOI:



      The aim of this study was to assess the prognostic value of metastatic lymph node (LN) ratio (MLNR) in stage III rectal cancer and whether this prognostic value remains significant when <12 LNs are retrieved.


      This prospective study included 115 patients with stage III rectal cancer from 2006 to 2010. All patients underwent neoadjuvant long-course chemoradiation, curative resection, and postoperative adjuvant therapy (5-fluorouracil and leucovorin). Data collected included demographics, tumor pathology, tumor-node-metastasis staging, number of LNs retrieved, MLNR, recurrence, and mortality.


      The mean number of examined LNs was 12.1, and the mean number of metastatic LNs was 3.5 (range, 1 to 19). The mean MLNR was .37 (range, 0 to 1.00). The mean duration of follow-up was 37 months (range, 24 to 63). Forty patients died during the follow-up period (overall mortality, 34.8%), only 31 because of cancer (cancer-specific mortality, 27%). Univariate analysis revealed that ypN stage, lymphovascular invasion, and follow-up duration were significantly associated with increased recurrence and decreased survival. Number of positive nodes and ypT stage significantly affected recurrence, with no effect on overall survival. Multivariate analysis proved that MLNR was the only independent risk factor for both mortality and recurrence. Prognostic capability was not affected by having <12 nodes retrieved. The best sensitivity and specificity of MLNR as a prognostic factor for both tumor recurrence and overall survival were achieved at a cutoff value of .375.


      MLNR is an independent prognostic factor for recurrence and survival after the resection of stage III rectal cancer, with high sensitivity and specificity in patients who received neoadjuvant chemoradiation and postoperative chemotherapy. The total number of LN retrieved did not affect the prognostic value of MLNR even if <12.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kehoe J.
        • Khatri V.P.
        Staging and prognosis of colon cancer.
        Surg Oncol Clin N Am. 2006; 15: 129-146
        • Morris E.J.
        • Maughan N.J.
        • Forman D.
        • et al.
        Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology.
        Gut. 2007; 56: 1419-1425
        • Compton C.C.
        • Fielding L.P.
        • Burgart L.J.
        • et al.
        Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.
        Arch Pathol Lab Med. 2000; 124: 979-994
        • Park Y.J.
        • Youk E.G.
        • Choi H.S.
        • et al.
        Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors.
        Int J Colorectal Dis. 1999; 14: 101-106
        • Harisi R.
        • Schaff Z.
        • Flautner L.
        • et al.
        Evaluation and comparison of the clinical, surgical and pathological TNM staging of colorectal cancer.
        Hepatogastroenterology. 2008; 55: 66-72
        • Greene F.L.
        Current TNM staging of colorectal cancer.
        Lancet Oncol. 2007; 8: 572-573
        • Kim K.H.
        • Yang S.S.
        • Yoon Y.S.
        • et al.
        Validation of the seventh edition of the American Joint Committee on Cancer tumor-node-metastasis (AJCC TNM) staging in patients with stage II and stage III colorectal carcinoma: analysis of 2511 cases from a medical centre in Korea.
        Colorectal Dis. 2011; 13: e220-e226
        • Peschaud F.
        • Benoist S.
        • Julie C.
        • et al.
        The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer.
        Ann Surg. 2008; 248: 1067-1073
        • Rosenberg R.
        • Friederichs J.
        • Schuster T.
        • et al.
        Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period.
        Ann Surg. 2008; 248: 968-978
        • Wang H.
        • Safar B.
        • Wexner S.
        • et al.
        Lymph node harvest after proctectomy for invasive rectal adenocarcinoma following neoadjuvant therapy: does the same standard apply?.
        Dis Colon Rectum. 2009; 52: 549-557
        • Kobayashi H.
        • Mochizuki H.
        • Kato T.
        • et al.
        Lymph node ratio is a powerful prognostic index in patients with stage III distal rectal cancer: a Japanese multicenter study.
        Int J Colorectal Dis. 2011; 26: 891-896
        • Kim Y.S.
        • Kim J.H.
        • Yoon S.M.
        • et al.
        Lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.
        Int J Radiat Oncol Biol Phys. 2009; 74: 796-802
        • Priolli D.G.
        • Cardinalli I.A.
        • Pereira J.A.
        • et al.
        Metastatic lymph node ratio as an independent prognostic variable in colorectal cancer: study of 113 patients.
        Tech Coloproctol. 2009; 13: 113-121
        • Dekker J.W.
        • Peeters K.C.
        • Putter H.
        • et al.
        Metastatic lymph node ratio in stage III rectal cancer; prognostic significance in addition to the 7th edition of the TNM classification.
        Eur J Surg Oncol. 2011; 36: 1180-1186
        • Dhar D.K.
        • Yoshimura H.
        • Kinukawa N.
        • et al.
        Metastatic lymph node size and colorectal cancer prognosis.
        J Am Coll Surg. 2005; 200: 20-28
        • Edge S.B.
        • Compton C.C.
        The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.
        Ann Surg Oncol. 2011; 17: 1471-1474
        • Damin D.C.
        • Rosito M.A.
        • Contu P.C.
        • et al.
        Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer.
        J Gastrointest Surg. 2011; 16: 1573-1580
        • de la Fuente S.G.
        • Manson R.J.
        • Ludwig K.A.
        • et al.
        Neoadjuvant CRT for rectal cancer reduces lymph node harvest in proctectomy specimens.
        J Gastrointest Surg. 2009; 13: 269-274
        • Kang J.
        • Hur H.
        • Min B.S.
        • et al.
        Prognostic impact of the lymph node ratio in rectal cancer patients who underwent preoperative CRT.
        J Surg Oncol. 2011; 104: 53-58
        • Edler D.
        • Ohrling K.
        • Hallstrom M.
        • et al.
        The number of analyzed lymph nodes—a prognostic factor in colorectal cancer.
        Acta Oncol. 2007; 46: 975-981
        • Manilich E.A.
        • Kiran R.P.
        • Radivoyevitch T.
        • et al.
        A novel data-driven prognostic model for staging of colorectal cancer.
        J Am Coll Surg. 2011; 213: 579-588
        • Osti M.F.
        • Valeriani M.
        • Masoni L.
        • et al.
        Neoadjuvant CRT for locally advanced carcinoma of the rectum.
        Tumori. 2004; 90: 303-309
        • Baxter N.N.
        • Morris A.M.
        • Rothenberger D.A.
        • et al.
        Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis.
        Int J Radiat Oncol Biol Phys. 2005; 61: 426-431
        • Wijesuriya R.E.
        • Deen K.I.
        • Hewavisenthi J.
        • et al.
        Neoadjuvant therapy for rectal cancer down-stages the tumor but reduces lymph node harvest significantly.
        Surg Today. 2005; 35: 442-445
        • Klos C.L.
        • Bordeianou L.G.
        • Sylla P.
        • et al.
        The prognostic value of lymph node ratio after neoadjuvant CRT and rectal cancer surgery.
        Dis Colon Rectum. 2011; 54: 171-175
        • Taflampas P.
        • Christodoulakis M.
        • Gourtsoyianni S.
        • et al.
        The effect of preoperative chemoradiotherapy on lymph node harvest after total mesorectal excision for rectal cancer.
        Dis Colon Rectum. 2009; 52: 1470-1474
        • Leibold T.
        • Shia J.
        • Ruo L.
        • et al.
        Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy.
        J Clin Oncol. 2008; 26: 2106-2111
        • Ceelen W.
        • Van Nieuwenhove Y.
        • Pattyn P.
        Prognostic value of the lymph node ratio in stage III colorectal cancer: a systematic review.
        Ann Surg Oncol. 2010; 17: 2847-2855
        • Collette L.
        • Bosset J.F.
        • den Dulk M.
        • et al.
        Patients with curative resection of cT3–4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.
        J Clin Oncol. 2007; 25: 4379-4386
        • Bujko K.
        • Glynne-Jones R.
        • Bujko M.
        Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials.
        Ann Oncol. 2010; 21: 1743-1750